Company profile
Acorda Therapeutics company profile
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://www.acorda.com/
- Contact email
- [email protected]
- Phone number
- (914) 347-4300
- Operating status
- Closed
- Company type
- For Profit
- Employee range
- 00251-00500 employees
- Revenue range
- $100K+
- Founded
- 1995-01-01
Headquarters
- Headquarters
- Springfield, Nebraska, United States
- Postal code
- 10532
- Country code
- US
- Continent
- North America